rosine kinases are important in cell signaling and have
been targets for other drugs such as imatanib mesylate
(Gleevec(R)), which is approved for treatment of certain leukemias.
New drug or biological candidates targeting B-cells, including the
recently approved rituximab (Rituxan(R)) for lymphomas and
rheumatoid arthritis, are aimed at eliminating abnormally
functioning B-cells.
About Pharmacyclics
Pharmacyclics is a pharmaceutical company developing innovative
products to treat cancer and other serious diseases. The company is
leveraging its small-molecule drug development expertise to build a
pipeline in oncology and other diseases based on a wide range of
targets, pathways and mechanisms. Its lead product, Xcytrin(R)
(motexafin gadolinium) Injection, has completed Phase 3 clinical
trials and several ongoing Phase 1 and Phase 2 clinical trials are
evaluating Xcytrin as a single agent or in combination with
chemotherapy and/or radiation in multiple cancer types. More
information about the company, its technology, and products can be
found at www.pharmacyclics.com.
Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are
registered trademarks of Pharmacyclics, Inc.
Gleevec(R) is a registered trademark of Novartis.
Rituxan(R) is a registered trademark of Genentech and Biogen
Idec.
NOTE: Other than statements of historical fact, the statements
made in this press release about plans for our NDA filing,
enrollment and future plans for our clinical trials, progress of
and reports of results from preclinical and clinical studies,
clinical development plans and product development activities are
forward-looking statements, as defined in the Private Securities
Litigation Reform Act of 1995. The words "believe," "will," "may,"
"continue," "plan," "expect," "intend," "anticipate," variations of
such words, and similar expressions also identify forward-looking
statements, b
'"/>
Page: 1 2 3 4 5 Related medicine technology :1.
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2
Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat
Recurrent Non-Small Cell Lung Cancer2.
Pharmacyclics Announces Promising Results From Phase 2 Clinical
Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung
Cancer3.
Pharmacyclics Announces Presentations and Published Abstracts on
Xcytrin at The 2007 American Society of Clinical Oncology Annual
Meeting4.
Pharmacyclics Announces Presentations on Its Novel and Selective
HDAC and Brutons Tyrosine Kinase Inhibitor Compounds5.
CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of
Action for Ranexa6.
Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug,
AN2690; Findings Published in Science7.
ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis
in Real-World Use of Drug-Eluting Stents8.
NIDA Study Identifies Genes That Might Help Some People Abstain
from Smoking9.
Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV
Activity10.
Study in Cell by Magen BioSciences Co-Founder David E. Fisher
Identifies New Roles in Skin Cancer Prevention for Key Tumor
Suppressor Protein11.
BioLineRx Presents Data on BL-1040 at Cardiovascular
Revascularization Therapies Conference Demonstrating Potential to
Reduce Deterioration of Infarcted Heart Tissue and Maintain
Functionality